Clinical trials: Age Related Maculopathy
Cataract, Glaucoma
Village-Integrated Eye Worker Trial II - Pilot
The vast majority of blindness is avoidable. The World Health Organization (WHO) estimates that 80% of cases of visual impairment could be prevented or reversed with early diagnosis and treatment.
- Conditions
- Cataract, Glaucoma, Age Related Macular Degeneration, Diabetic Retinopathy
- Trial name
- VIEW II Pilot (NCT03278587)
- Testing
- Community-based screening program, Cataract camp program, Community health worker program
- Where
- Nepal
- Volunteers
- 87,992 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Macular Degeneration
The Optical Coherence Tomography in Age-Related Macular Degeneration Study: The OCT in AMD Study
The Optical Coherence Tomography (OCT) is a non-contact, non invasive method to examine the retina by providing cross-sectional scans through the retina.
- Trial name
- NCT00531141
- Testing
- examination only
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Age-related Macular Degeneration, Stargardt Disease
Efficacy of Acupuncture in Macular Diseases
This is a single-arm study designed to assess the efficacy of acupuncture (Traditional Chinese Medicine) for chronic macular diseases of several types.
- Conditions
- Age-related Macular Degeneration, Stargardt Disease, Macular Dystrophy
- Trial name
- AMAD (NCT02255981)
- Testing
- Acupuncture and massage
- Where
- 2 sites in Colombia
- Volunteers
- 33 people
- Sponsor
- Escuela Neijing
Age-Related Macular Degeneration, Diabetic Retinopathy
Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations
In this study, participants will be imaged using two Optical Coherence Tomography (OCT) devices: device N, a standard conventional OCT device with an invention (comfortable chin and forehead rest that can be adjusted to fit each…
- Conditions
- Age-Related Macular Degeneration, Diabetic Retinopathy, Central Serous Chorioretinopathy, Glaucoma
- Trial name
- NCT05686421
- Testing
- OCT Imaging Using Device N, OCT Imaging Using Device C
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Choroidal Neovascularization, Macular Degeneration
Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration
Age-related macular degeneration (AMD) represents the most common cause of blindness in patients over the age of 60. The major cause of vision loss in this disease is due to the development of choroidal neovascular membrane…
- Trial name
- NCT00001615
- Testing
- Corticosteroid
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Eye Institute (NEI)
Dry Age Related Macular Degeneration
Hyperspectral Drusen Classification
This observational, cross-sectional study is designed to explore the feasibility to extract spatial-spectral features from hyperspectral retinal images captured with Optina Diagnostics' MHRC that are characteristic to the…
- Trial name
- NCT06860555
- Testing
- Mydriatic Hyperspectral retinal Camera, (MHRC) and Optical coherence tomography (OCT)
- Where
- Canada
- Volunteers
- 112 people
- Sponsor
- Optina Diagnostics Inc.
Neovascular Age-related Macular Degeneration
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
- Trial name
- ShORe (NCT04757610)
- Testing
- 2.0 mg OPT-302, 0.5 mg ranibizumab
- Where
- 191 sites in United States, Argentina and 22 more
- Volunteers
- 986 people
- Sponsor
- Opthea Limited
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Supplemental Adjuvants for Intracellular Nutrition and Treatment
Nutritional supplements have an augmentative effect on the outcomes of standard treatment of diabetic macular edema (DME) and Neovascular Age-Related Macular Degeneration (NAMD).
- Trial name
- SAINTS (NCT00893724)
- Testing
- Neutral pills with no medicinal effect, Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals, Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mid-Atlantic Retina Consultations, Inc.
Age-related Macular Degeneration
Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Patients will receive injections of ranibizumab.
- Trial name
- MAKO (NCT02727881)
- Testing
- Squalamine lactate ophthalmic solution, 0.2%, ranibizumab
- Where
- 118 sites in United States
- Volunteers
- 230 people
- Sponsor
- Ohr Pharmaceutical Inc.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants
The primary objective of this study is to evaluate the safety and tolerability of D-4517.2 after single subcutaneous (SC) doses in healthy participants.
- Trial name
- NCT05105607
- Testing
- D-4517.2
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Age-Related Macular Degeneration (ARMD)
Can the Risk for AMD be Modulated?
The goal of this Cross-sectional, interventional study is to learn about whether different risk factors, as Mediterranean diet, lifestyle and concomitant medication can modulate the risk imprinted by genetics in Age-related…
- Trial name
- AMD_LifeGene (NCT05735730)
- Testing
- Blood draw
- Where
- Portugal
- Volunteers
- 1,800 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Age-related Macular Degeneration
Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration
The purpose of this study is to compare 12-month results of two single initial treatments-photodynamic therapy with verteporfin alone and this therapy combined with intravitreal bevacizumab-for neovascular age-related macular…
- Trial name
- NCT01032109
- Testing
- Bevacizumab
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Kumamoto University
Age-Related Macular Degeneration
Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - SUMMIT (Part 2)
We will conduct a prospective, non-interventional roll-over extension of the PINNACLE study (Deciphering AMD by deep phenotyping and machine learning).
- Trial name
- NCT06682455
- Where
- 8 sites in Austria, United Kingdom
- Volunteers
- 300 people
- Sponsor
- University of Southampton
Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion
Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy
This is a single-arm, multicenter study to evaluate clinical usability of a pre-filled syringe containing SCD411 in adult patients with neovascular Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO)…
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy
- Trial name
- NCT07501052
- Testing
- SCD411 0.05mL (2mg)
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
- Trial name
- NCT07516132
- Testing
- OTX-TKI
- Where
- 8 sites in United States
- Volunteers
- 850 people
- Sponsor
- Ocular Therapeutix, Inc.
Wet Macular Degeneration
Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to…
- Trial name
- NCT02541084
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 72 people
- Sponsor
- Bayer
Degeneration of Macula and Posterior Pole
Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis
Significant difference in the parameter settings of early optical coherence tomography (OCT spectal domain) in patients with subfoveal neovascular membrane realacionada age after treatment with a single intravitreal injection of…
- Trial name
- NCT01669447
- Testing
- ranibizumab
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Osias Francisco de Souza
Neovascular Age-Related Macular Degeneration
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).
- Trial name
- ONYX (NCT02713204)
- Testing
- REGN910-3, Intravitreal Aflibercept Injection (IAI)
- Where
- 87 sites in United States
- Volunteers
- 365 people
- Sponsor
- Regeneron Pharmaceuticals
Submacular Hemorrhage, Wet Macular Degeneration
Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration
This study will define the limits of subretinal hemorrhage parameters that are consistent with a good visual outcome with aggressive anti-VEGF treatment in patients with neovascular age-related macular degeneration (NVAMD).
- Conditions
- Submacular Hemorrhage, Wet Macular Degeneration, Neovascular Age-related Macular Degeneration
- Trial name
- NCT03699618
- Testing
- Anti-VEGF, Hemorrhage displacement + Anti-VEGF
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Macular Degeneration, Wet Macular Degeneration
EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)
- Trial name
- EAGLE (NCT02689518)
- Testing
- Intravitreal aflibercept injection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.